Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates

Core Insights - Entera Bio Ltd. reported strong execution and key milestones in its N-Tab™ oral peptide programs, with a significant upcoming FDA ruling on the ASBMR-FNIH SABRE regulatory endpoint for osteoporosis drugs, which is seen as a major catalyst for its product EB613 [2][3] Financial Performance - As of June 30, 2024, Entera had cash and cash equivalents of $9.1 million, sufficient to meet projected operating requirements into Q3 2025 [6] - Research and development expenses for Q2 2024 were $1.1 million, a decrease from $1.2 million in Q2 2023, primarily due to reduced clinical expenses [7] - General and administrative expenses remained stable at $1.1 million for both Q2 2024 and Q2 2023 [8] - Total operating expenses for Q2 2024 were $2.2 million, down from $2.3 million in Q2 2023, with a net loss of $2.1 million or $0.06 per share, compared to a net loss of $2.3 million or $0.08 per share in the previous year [8][15] Product Development Updates - EB613, the first oral PTH(1-34) daily osteoanabolic tablet for osteoporosis, is preparing for a pivotal study targeting a wider population, with a Phase 2 study already meeting its primary and secondary endpoints [3][9] - EB612, focused on hypoparathyroidism, is moving towards Phase 2 development following positive Phase 1 clinical data presented in June 2024 [4] - Entera is also developing the first oral GLP-2 peptide tablets for short bowel syndrome and oral oxyntomodulin for obesity, with pharmacological data expected in the second half of 2024 [5][9]